Developments AzurRx BioPharma reports positive interim data from Phase 2 cystic fibrosis trial AzurRx BioPharma (NASDAQ:AZRX) reported positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients... August 12, 2020